European experience of cladribine tablets in elderly patients with multiple sclerosis: Could it be the last treatment?

Background Recent studies support the need for early and intensive disease-modifying treatment (DMT) for patients with multiple sclerosis (PWMS). Abrupt DMT withdrawal may risk disease reactivation. Recent studies showed that MS disease activity was not rare after DMT withdrawal for PWMS aged >45/55...

Descripció completa

Dades bibliogràfiques

Autors principals:	Jérôme de Seze, Chiara Zecca, Giovanni Castelnovo, Xavier Ayrignac, Patrick Vermersch, Claudio Gobbi, Giulia Mallucci, Clarisse Carra-Dallière, Pierre Labauge, Kévin Bigaut, Laurent Kremer, Nicolas Collongues, Livia Lanotte, Eric Thouvenot, Christine Ernon, Dominique Dive
Format:	Artigo
Idioma:	Inglês
Publicat:	SAGE Publishing 2025-01-01
Col·lecció:	Multiple Sclerosis Journal - Experimental, Translational and Clinical
Accés en línia:	https://doi.org/10.1177/20552173251321810
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!